Edition:
United States

Akcea Therapeutics Inc (AKCA.OQ)

AKCA.OQ on NASDAQ Stock Exchange Global Select Market

19.88USD
10:26am EST
Change (% chg)

$0.45 (+2.32%)
Prev Close
$19.43
Open
$19.62
Day's High
$20.55
Day's Low
$19.62
Volume
30,259
Avg. Vol
126,957
52-wk High
$31.23
52-wk Low
$8.10

Latest Key Developments (Source: Significant Developments)

Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen
Wednesday, 15 Nov 2017 07:00am EST 

Nov 15 (Reuters) - Akcea Therapeutics Inc :Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS.Akcea Therapeutics Inc - ‍in U.S., Food And Drug Administration assigned a prescription drug user fee act goal date of August 30, 2018​.Akcea Therapeutics Inc - marketing applications for Volanesorsen been accepted for review in U.S., EU & Canada for treatment of patients with FCS.  Full Article

Akcea initiates AKCEA-ANGPTL3-LRx Phase 2 program in patients with rare hyperlipidemias
Monday, 13 Nov 2017 04:15pm EST 

Nov 13 (Reuters) - Akcea Therapeutics Inc :Akcea initiates AKCEA-ANGPTL3-LRx Phase 2 program in patients with rare hyperlipidemias.Akcea Therapeutics Inc - ‍AKCEA-ANGPTl3-L(Rx )is designed to reduce production of angiopoietin-like 3, or ANGPTL3​.  Full Article

Akcea Therapeutics Q3 loss per share $0.27
Monday, 6 Nov 2017 04:05pm EST 

Nov 6 (Reuters) - Akcea Therapeutics Inc :Q3 loss per share $0.27.Akcea Therapeutics Inc qtrly ‍revenue $13.4 million​.Q3 earnings per share view $-0.19, revenue view $11.9 million -- Thomson Reuters I/B/E/S.  Full Article

Akcea Therapeutics establishes Canadian subsidiary
Wednesday, 6 Sep 2017 07:00am EDT 

Sept 6 (Reuters) - Akcea Therapeutics Inc :Akcea Therapeutics Inc - Establishment of Ottawa-based Canadian unit and appointment of Jared Rhines as general manager for Akcea Therapeutics Canada.  Full Article

Akcea and Ionis submits New Drug Application for volanesorsen to FDA
Thursday, 31 Aug 2017 07:00am EDT 

Aug 31 (Reuters) - Akcea Therapeutics Inc :Akcea and Ionis announce submission of new drug application for volanesorsen to the U.S. FDA.Akcea Therapeutics Inc - also on track to launch volanesorsen globally in 2018 pending approval in respective markets​.Akcea Therapeutics Inc - ‍on track to submit application for marketing authorization in Canada in September for volanesorsen​.  Full Article

Akcea Q2 loss per share $0.41
Tuesday, 8 Aug 2017 07:00am EDT 

Aug 8 (Reuters) - Akcea Therapeutics Inc ::Akcea reports financial results and highlights for second quarter 2017.Q2 loss per share $0.41.Akcea Therapeutics Inc - ‍expects its g&a expenses to continue to increase as company continues to prepare to launch volanesorsen​.Akcea Therapeutics Inc - ‍Akcea's revenue for three ended june 30, 2017 was $14.1 million​.  Full Article

Akcea, Ionis announce submission of marketing authorization application
Thursday, 27 Jul 2017 07:00am EDT 

July 27 (Reuters) - Akcea Therapeutics Inc ::Akcea and Ionis announce submission of marketing authorization application for volanesorsen to the European Medicines Agency.Akcea Therapeutics Inc - volanesorsen, if approved, will be commercialized by Akcea.  Full Article

Novartis reports 9.7 pct passive stake in Akcea Therapeutics as of July 19
Thursday, 27 Jul 2017 06:04am EDT 

July 27 (Reuters) - Akcea Therapeutics Inc :Novartis Pharma AG reports 9.7 percent passive stake in Akcea Therapeutics Inc as of July 19, 2017 - ‍​SEC filing.  Full Article

Akcea Therapeutics Inc shares open at $8.13 in debut vs IPO price of $8/share
Friday, 14 Jul 2017 12:08pm EDT 

July 14 (Reuters) - :Akcea Therapeutics Inc shares open at $8.13 in debut on the NASDAQ versus IPO price of $8.00 per share.  Full Article

Akcea Therapeutics says public offering of 15.6 mln common shares priced at $8 per share
Thursday, 13 Jul 2017 08:25pm EDT 

July 13 (Reuters) - Akcea Therapeutics Inc :Akcea therapeutics announces pricing of initial public offering.Says initial public offering of 15.6 million common shares priced at $8.00per share.Akcea therapeutics - agreed to purchase $50 million of common stock in private placement with completion of co's ipo at price per share equal to ipo price.  Full Article

BRIEF-Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen

* Akcea and Ionis announce acceptance of marketing applications in U.S., EU and Canada for Volanesorsen for the treatment of FCS